When should pimobendan be initiated in a 5-year-old spaye...
By DVM Rounds·April 5, 2026·1 question
❤️Cardiology
🧭 Routing
Routed to Cardiology for dog case
❤️Amara ObiCardiology Specialist
Thank you for reaching out regarding this Cavalier King Charles Spaniel. This is a classic presentation, and your precise description of the murmur and echocardiographic findings is very helpful.
Based on the information provided – a 5-year-old asymptomatic Cavalier King Charles Spaniel with a Grade 3/6 left apical systolic murmur and echocardiographic evidence of significant cardiac remodeling (LA:Ao > 1.6 and LVIDdN > 1.7) – this patient meets the criteria for ACVIM Stage B2 Myxomatous Mitral Valve Disease (DMVD).
Initiation of Pimobendan:
Pimobendan should be initiated immediately for this patient. The landmark EPIC (Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease) trial definitively demonstrated that starting pimobendan in dogs with ACVIM Stage B2 DMVD significantly delays the onset of clinical signs of congestive heart failure (CHF) by an average of 15 months and extends survival time.
Pimobendan is an inodilator, meaning it has both positive inotropic effects (improving myocardial contractility) and vasodilatory effects (reducing both preload and afterload). In Stage B2 DMVD, these actions help to improve cardiac efficiency, reduce the workload on the heart, and mitigate the progression of adverse cardiac remodeling.
Dosing and Administration:
The recommended dose for canine pimobendan is:
* Pimobendan: 0.25-0.3 mg/kg PO Every 12 hours
It is crucial that pimobendan be administered on an empty stomach, approximately one hour before feeding. Food significantly reduces its bioavailability by about 30%, which can compromise its therapeutic efficacy.
Additional Management and Monitoring:
ACE Inhibitors: While pimobendan is the cornerstone for B2 DMVD, an ACE inhibitor like enalapril or benazepril can be considered, although the evidence for a survival benefit in B2 is weaker than for pimobendan. If you choose to add one, monitor renal values and electrolytes 5-7 days after initiation.
* Enalapril: 0.5 mg/kg PO Every 12-24 hours
* Benazepril: 0.25-0.5 mg/kg PO Every 12-24 hours
Furosemide is NOT Indicated: I want to emphasize that since this patient is asymptomatic and not in congestive heart failure, furosemide should not be started. Administering diuretics at this stage can lead to dehydration, azotemia, electrolyte imbalances, and activation of the renin-angiotensin-aldosterone system (RAAS) without providing any clinical benefit. The distinction between "heart disease" and "heart failure" is critical here.
Sleeping Respiratory Rate (SRR): Please instruct the owner to monitor and record the dog's sleeping respiratory rate at home daily. This is the single most sensitive early indicator of impending CHF. A normal SRR is typically less than 30 breaths per minute. Any sustained increase above this threshold, or a trend of increasing SRR, should prompt immediate re-evaluation.
Recheck Echocardiogram: I would recommend a recheck echocardiogram in 6-12 months to monitor disease progression and assess response to therapy.
By initiating pimobendan now, you are taking the most evidence-based step to provide this patient with a better quality of life and potentially extend her time before she experiences the clinical signs of heart failure.
Please let me know if you have any further questions or if the patient's condition changes.
Based on the information provided – a 5-year-old asymptomatic Cavalier King Charles Spaniel with a Grade 3/6 left apical systolic murmur and echocardiographic evidence of significant cardiac remodeling (LA:Ao > 1.6 and LVIDdN > 1.7) – this patient meets the criteria for ACVIM Stage B2 Myxomatous Mitral Valve Disease (DMVD).
Initiation of Pimobendan:
Pimobendan should be initiated immediately for this patient. The landmark EPIC (Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease) trial definitively demonstrated that starting pimobendan in dogs with ACVIM Stage B2 DMVD significantly delays the onset of clinical signs of congestive heart failure (CHF) by an average of 15 months and extends survival time.
Pimobendan is an inodilator, meaning it has both positive inotropic effects (improving myocardial contractility) and vasodilatory effects (reducing both preload and afterload). In Stage B2 DMVD, these actions help to improve cardiac efficiency, reduce the workload on the heart, and mitigate the progression of adverse cardiac remodeling.
Dosing and Administration:
The recommended dose for canine pimobendan is:
* Pimobendan: 0.25-0.3 mg/kg PO Every 12 hours
It is crucial that pimobendan be administered on an empty stomach, approximately one hour before feeding. Food significantly reduces its bioavailability by about 30%, which can compromise its therapeutic efficacy.
Additional Management and Monitoring:
* Enalapril: 0.5 mg/kg PO Every 12-24 hours
* Benazepril: 0.25-0.5 mg/kg PO Every 12-24 hours
By initiating pimobendan now, you are taking the most evidence-based step to provide this patient with a better quality of life and potentially extend her time before she experiences the clinical signs of heart failure.
Please let me know if you have any further questions or if the patient's condition changes.
Related Cases
A 7-year-old intact female Cavalier King Charles Spaniel ...
❤️ Cardiology
1 question
A 9-year-old neutered male Boxer presents with a cough, i...
❤️ Cardiology
1 question
An 8-year-old intact female Cavalier King Charles Spaniel...
❤️ Cardiology
1 question
A 5-year-old intact male Doberman Pinscher presents with ...
❤️ Cardiology
1 question
A 7-year-old intact male Cavalier King Charles Spaniel wi...
❤️ Cardiology
1 question
What is the best initial diagnostic workup for a 4-year-o...
❤️ Cardiology
1 question
Get Instant Specialist Consults
DVM Rounds connects you with 13 AI veterinary specialists and 45+ sub-agents. Ask any clinical question and get comprehensive, multi-specialist answers in seconds.
Start Free — No Credit Card